5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
There are no Transcripts on TXMD.
Business Wire (Mon, 4:05PM)
Business Wire (Feb 25, 2014)
at CNBC.com (Jan 30, 2014)
Business Wire (Dec 18, 2013)
Business Wire (Dec 4, 2013)
TXMD vs. ETF Alternatives
Monday, Mar 35:04 PM
Tuesday, Jan 289:35 AM
Tuesday, Jan 289:35 AM| Comment!
- TherapeuticsMD's (TXMD) Estradiol VagiCap vaginal capsule for the treatment of vulvar vaginal atrophy (VVA) in post-menopausal women performed well in two trials when compared with NovoNordisks (NVO) Vagifem.
- The results of the studies showed substantially lower systemic exposure to the estradiol hormone of the VagiCap - also known as TX 12-004-HR - vs Vagifem.
- VVA affects up to 50% of postmenopausal women and is a result of a decrease in estrogen.
- TherapeuticsMD's shares are +7.8%. (PR)
Tuesday, Jan 289:10 AM
Friday, Jan 109:55 AM
Friday, Jan 109:55 AM| Comment!
- "New data will provide a measure of blood concentration compared to the referenced listed drug VagiFem," Noble Financial's Nathan Cali says, referencing TherapeuticsMD's (TXMD +9.2%) bio-identical 17ß-estradiol and progesterone candidate, TX 12-001HR.
- The analyst says the company likely has enough cash to last until FDA approval.
- Buy rating and $7.25 target maintained.
- See also: TXMD achieves 50th site for Phase 3 study
Thursday, Dec 52013, 1:50 PM
Thursday, Dec 52013, 1:50 PM| Comment!
- Noble Financial analyst Nathan Cali is excited about TherapeuticsMD's (TXMD +2.6%) move to appoint Joel Krasnow as CSO and head of regulatory development.
- Dr. Krasnow's experience provides TXMD with a well rounded clinical team to execute Phase 3 studies towards FDA approval for three late stage compounds; potential FDA approvals expected to start in 2015, Cali says.
- Buy rating maintained.
- Price target is $7.25.
Tuesday, Aug 62013, 5:12 PM
Monday, Jul 12013, 4:40 PMAnnual reconstitution of Russell’s U.S. indexes may help explain some of today's big movers among smallcaps; the event typically is viewed as a trading opportunity. Among Russell deletions: AMBT +22.4%, ACUR +18%, DM +14.7%, FALC -12.4%, CDZI +12.4%, HNR +10.9%, Among additions: INSM -18.7%, TXMD -13.5%, YRCW +10%. (full list) |Monday, Jul 12013, 4:40 PM| 5 Comments
Monday, Jul 12013, 12:45 PM